AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
AmoyDx Distributors Annual Meeting 2021
Xiamen, China, December 10, 2021 - Amoy Diagnostics Co. Ltd. (AmoyDx) Distributors Annual Meeting 2021 was held recently. Over 100 delegates from about 40 countries or regions gathered together virtually.
Amoy Diagnostics and Janssen China Sign MoU on Strategic Collaboration
Xiamen China, December 9, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) recently signed a Memorandum of Understanding (MoU) on strategic collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson. In this cooperation, both par
Visit AmoyDx at ESGO 2021 in Prague, Czech Republic
AmoyDx will be exhibiting at ESGO in Prague, Czech Republic from 23 Oct. - 25 Oct. 2021. Please block your calendar and be sure to stop by our booth 6#, 2nd floor, Prague Congress Centre.
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market
Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
* Required information
Manage your account info
Change your password